RICHMOND, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- BioAge Labs (Nasdaq: BIOA) (“BioAge”, “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will present at the Goldman Sachs Second Annual “Year-Ahead” Catalyst Clinic on Thursday, December 19, 2024, 11–12 PM EST. To access the live webcast of the virtual presentation, register here. Replays of the webcast will be ...

RICHMOND, Calif., Nov. 21, 2024 (GLOBE NEWSWIRE) -- BioAge Labs (Nasdaq: BIOA) (“BioAge”, “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will participate in the following upcoming investor conferences: Piper Sandler 36th Annual Healthcare Conference (New York, December 3-5, 2024): Kristen Fortney, PhD, CEO and co-founder, is scheduled to participate in a comp ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-42279 BIOAGE LABS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 47-4721157 ( State or other jurisdict ...

Clinical Trials and Drug Development - BioAge initiated the Phase 2 STRIDES trial for azelaprag in combination with tirzepatide for obesity treatment, with top-line results expected in Q3 2025[3] - Research and development expenses increased by $13.5 million to $20.0 million in Q3 2024, primarily due to the Phase 2 STRIDES trial and azelaprag manufacturing costs[5] - Azelaprag, BioAge's lead product candidate, is an oral small-molecule APJ agonist with potential to enhance weight loss and improve body composition in obesity therapy[9] - BioAge is developing NLRP3 inhibitors for neuroinflammatory diseases and has preclinical programs targeting metabolic aging pathways[10] Financial Performance and Funding - The company completed a $238.3 million IPO and private placement, with net proceeds of approximately $189.5 million, extending cash runway into 2029[1][4] - Net loss for Q3 2024 was $23.4 million, or $6.70 per share, compared to a net loss of $14.6 million, or $8.74 per share, in Q3 2023[7] - As of September 30, 2024, BioAge had $334.5 million in cash and cash equivalents, sufficient to fund operations into 2029[8] - Total IPO proceeds, including underwriters' additional share purchases, yielded approximately $217.1 million in net proceeds[4][8] Corporate Governance and Leadership - The company appointed Jean-Pierre Garnier, former CEO of GSK, as Chair of the Board of Directors[4] Operational Expenses - General and administrative expenses rose by $1.3 million to $4.7 million in Q3 2024, driven by increased stock-based compensation[6]

Initiated Phase 2 STRIDES trial of azelaprag in combination with tirzepatide for obesity Completed $238.3 million initial public offering and concurrent private placement, cash and cash equivalents sufficient to fund operations and capital expenditures into 2029 Appointed former GSK CEO Jean-Pierre Garnier as Board Chair RICHMOND, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge", “the Company”), a clinical-stage biotechnology company developing therapeutic product candidates for metabol ...